Evidence map›Paper›PMID 41678876›Full record

Trial reportMaturitas2026

Randomization to hormone therapy and changes in plasma biomarkers of Alzheimer's pathology: The women's health initiative memory study.

Aladdin H Shadyab, Bowei Zhang, Andrea Z LaCroix, Linda K McEvoy

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Maturitas, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00685009 (Women's Health Initiative Memory Study), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00685009 completednot on this map

Women's Health Initiative Memory Study

TypeobservationalSponsorNational Heart, Lung, and Blood Institute (NHLBI)Ran1996 to 2008Enrolled7,525ConditionsDementia SyndromesArmsEstrogen hormone therapy, Estrogen plus progesterone hormone therapy, Placebo
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Aladdin H ShadyabHerbert Wertheim School of Public Health and Human and Human Longevity Science, University of California San Diego, 9500 Gilman Drive #0725, La Jolla, CA, 92093, USA; Division of Geriatrics, Gerontology, and Palliative Care, Department of Medicine, University of California San Diego, 9500 Gilman Drive #0725, La Jolla, CA, 92093, USA. Electronic address: aladdinshadyab@health.ucsd.edu.
Bowei ZhangHerbert Wertheim School of Public Health and Human and Human Longevity Science, University of California San Diego, 9500 Gilman Drive #0725, La Jolla, CA, 92093, USA.
Andrea Z LaCroixHerbert Wertheim School of Public Health and Human and Human Longevity Science, University of California San Diego, 9500 Gilman Drive #0725, La Jolla, CA, 92093, USA.
Linda K McEvoyKaiser Permanente Washington Health Research Institute, 1730 Minor Ave, Seattle, WA 98101, USA.

Funding

Plasma Proteomic Signatures for Alzheimer's Disease and Related DementiasRF1AG079149 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MCEVOY, LINDA KATHLEEN, SHADYAB, ALADDIN · 2022 to 2022
$7.5M
Plasma Proteomic Signatures for Alzheimer's Disease and Related DementiasR01AG079149 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Linda Kathleen McEvoy, Aladdin Shadyab · 2025 to 2026
$2.4M
NIA NIH HHS R01 AG079149NIA NIH HHS RF1 AG079149
6 · The paper itself

Abstract

The association of hormone therapy with Alzheimer's pathology among postmenopausal women is not well understood. We examined the association of randomized assignment to hormone therapy with changes in plasma biomarkers of Alzheimer's pathology in the Women's Health Initiative Memory Study. Rates of change in the biomarkers (p-tau217, p-tau181, Aβ42:Aβ40, GFAP, and NfL) over an average 15-year follow-up did not significantly differ for estrogen alone vs placebo or estrogen plus progestin vs placebo. These null associations do not support either a protective or a detrimental association of hormone therapy of the types tested in the Women's Health Initiative with long-term changes in plasma Alzheimer's biomarkers. CLINICALTRIALS.GOV: NCT00685009.

Indexed as

Alzheimer DiseaseEstrogen Replacement TherapyEstrogensProgestinsAgedAmyloid beta-PeptidesBiomarkersFemaleGlial Fibrillary Acidic ProteinHumansMiddle AgedNeurofilament ProteinsPeptide FragmentsPostmenopausetau ProteinsWomen's HealthAmyloid beta-Peptidesamyloid beta-protein (1-42)BiomarkersEstrogensGFAP protein, humanGlial Fibrillary Acidic Proteinneurofilament protein LNeurofilament ProteinsPeptide FragmentsProgestinstau ProteinsAlzheimer's diseaseDementiaGFAPHormone therapyMenopauseNfLPlasma biomarkersP-tau217Women's health

Identifiers

PMID41678876
PMCPMC13077962

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.